Discussion of "Reciprocal Lending Relationships in Shadow Banking" by Yi Li and "Nonbank and Lending Standards in Mortgage Markets. The Spillovers from Liquidity Regulation." by Pedro Gete and Michael Reher

Prepared for The Clearing House/Columbia University Conference "Optimal Bank Liquidity Regulation" February 9, 2018

Seth Carpenter
Chief US Economics
Tel: +1-203-719 4173
seth.carpenter@ubs.com

This document has been prepared by UBS Securities LLC.
ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON SLIDE 15
Overview

- Two papers that discuss regulation and the effect on market intermediation
  - Li looks at money market mutual fund (MMF) interaction with banks.
  - Gete and Reher look at the general equilibrium effect of the liquidity coverage ratio on the market share of nonbanks in mortgage origination.
Reciprocal Lending Relationships in Shadow Banking (Li)

- The paper lays out the following:
  - MMFs are pushed to invest at shorter maturities.
  - Banks are pushed to borrow at longer maturities.
  - How do these agents resolve this tension?

- Reciprocal relationships—each side gives a little
Reciprocal Lending Relationships in Shadow Banking (Li)

- Why should it matter? Author pushes in two directions.
  - Presumably, if there is a more stable relationship, there is more financial stability, whether intended or not.
  - These relationships can lead to less diversification of risk, perhaps leading to fragility.
What would I have liked to see more of?

- Mapping the regression coefficients into market rates
  - For example, is Libor-OIS narrower as their micro-level results would suggest?
  - Is there in market data any reflection of differentials based on attachment of banks to MMFs?
Three-month Libor-OIS Spread

Libor-OIS spread

Source: UBS, Bloomberg
Reciprocal Lending Relationships in Shadow Banking (Li)

- NAV reform led to a sharp drop in Prime funds AUM.
- In 2016, Libor-OIS, 1s/3s, and 3s/6s widened notably. What does this paper tell us about that phenomenon?
MMMIF Reform led to a sharp decline in AUM for Prime Funds

Assets Under Management

Billions US$

Source: UBS, ICI
MMF Reform led to a fall in AUM and a spike in Libor-OIS

Prime Funds Assets Under Management and LIBOR-OIS

Source: UBS, ICI, Bloomberg
The authors make the following points:

- The LCR puts greater value on Ginnie Mae MBS over Fannie and Freddie MBS.
- This higher value pushes up Ginnie relative prices and creates more liquidity.
- These effects push nonbanks to produce relatively more Ginnie mortgages and takeover a bigger market share.
This question is a critical issue.

- Mortgages were an important part of the financial crisis and understanding how the world has changed is useful.

- The authors cite potential fiscal implications of FHA loans.

- The housing market is important to the US economy.
Nonbanks and Lending Standards in Mortgage Markets. The Spillovers from Liquidity Regulation. (Gete and Reher)

- Identification
  - Probably not as clean as the authors suggest.
  - Other regulation that was being implemented over time could be partially responsible.
  - The "credit box" is tighter for many reasons, perhaps driving some of the results.
  - Ultimately not that big a deal—the main point is very important.
Nonbanks and Lending Standards in Mortgage Markets. The Spillovers from Liquidity Regulation. (Gete and Reher)

- Where to look in the future?
  - The Fed balance sheet is unwinding. $8 billion per month of MBS going to the market.
  - The pace of the unwind will accelerate to up to $20 billion per month.
  - Authors note that nonbanks finance their inventories, and that cost could be affected by the Treasury-MBS basis.
In our projections in 2020, the Fed will buy Treasuries and sell MBS simultaneously.
Our baseline Fed balance sheet projections

The Fed will be buying Treasuries again in under 3 years

Source: UBS, FRB

Total Assets

Treasury Securities

MBS

Reserves

Source: UBS, FRB
Required Disclosures

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 8 February 2018 7:45 PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations.
Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.
Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo, in certain instances, UBS.com and any other system, or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com as an approved means for distributing Global Research (each a “System”). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client’s individual preferences as to the frequency and manner of receiving communications, a client’s risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that you shall be subject to this Global Research Disclaimer, where applicable the UBS Investment Bank terms of business (https://www.ubs.com/global/en/investment-bank/regulatory.html) and to UBS’s Terms of Use/Disclaimer (https://www.ubs.com/global/en/legalinfo2/disclaimer.html). In addition, you consent to UBS processing your personal data and using cookie technologies as further described in our Privacy Statement (http://www.ubs.com/global/en/legalinfo2/privacy.html) and cookie notice (http://www.ubs.com/global/en/homepage/cookies/cookie-management.html).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via a System or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, nor intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or a offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document represents a recommendation that any investment strategy or recommendation is suitable or appropriate to an investor’s individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further discards any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of an investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the information.

Prior to making any investment or financial decisions, any recipient of this document or the information should seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS’s internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the “Information”), except with respect to Information UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent that third party’s interpretation of the data, information and/or opinions provided by that third party either publicly or in connection with a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any material contained in the Information (including any forecast, value, index or other calculated amount (“Values”)) be used for any of the following purposes:

(i) valuation or accounting purposes;
(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
(iii) to measure the performance of any financial instrument, including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any Information for any of the above purposes or otherwise rely upon this document or any Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/dislosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking revenues are a part, or involves investment banking revenues in a material way.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the Investment Bank Union laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Prior to making any investment or financial decisions, any recipient of this document or the information should seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS’s internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the “Information”), except with respect to Information UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent that third party’s interpretation of the data, information and/or opinions provided by that third party either publicly or in connection with a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any material contained in the Information (including any forecast, value, index or other calculated amount (“Values”)) be used for any of the following purposes:

(i) valuation or accounting purposes;
(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
(iii) to measure the performance of any financial instrument, including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any Information for any of the above purposes or otherwise rely upon this document or any Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/dislosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking revenues are a part, or involves investment banking revenues in a material way.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the Investment Bank Union laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.
Contact Information

UBS Securities LLC
1285 Avenue of the Americas
New York, NY 10128

Tel: 203 719 1252

www.ubs.com